Search results
3 companies and 23 research reports found for "IS Pharma"
Company results
- IS Pharma
IS Pharma is a speciality pharmaceutical and medical devices firm focused on the specialist hospital...
- Sunesis Pharmaceuticals
Sunesis Pharmaceuticals is US biotech company focused on the development of anticancer drugs. Its le...
- Clavis Pharma
Clavis has two Phase III cancer therapies. CP-4126 (improved gemcitabine) targets pancreatic cancer;...
Sector reports
No sector reports have been found.
Research results
Vernalis
Positioned for 2012
Update | Pharmaceutical & Healthcare | 19/04/2012Vernalis’ three-tier business strategy (commercial, development, research) has been subtly refined following the closure of its recent £65....
Sunesis Pharmaceuticals
He who would valiant be
Update | Pharmaceutical & Healthcare | 04/04/2012Sunesis’s courageous attempt to develop what could be the first new therapeutic agent in decades in acute myeloid leukaemia (AML) seems aptly de...
Sunesis Pharmaceuticals
Interim analysis in Q3
Update | Pharmaceutical & Healthcare | 19/03/2012Sunesis is moving closer to its key 2012 event, namely the interim analysis of its pivotal VALOR Phase III study of vosaroxin in relapsed/refractory a...
Clavis Pharma
Resistance is useless
Outlook | Pharmaceutical & Healthcare | 28/02/2012Clavis Pharma develops cancer therapies with improved delivery characteristics that also overcome low hENT1, a widespread drug resistance mechanism to...
Vernalis
Worth the wait
Update | Pharmaceutical & Healthcare | 24/02/2012Vernalis’s proposed £65.9m equity raise (net of costs) and multi-product in-licensing deal with private US company Tris Pharma are the late...
Sunesis Pharmaceuticals
Large IST in AML/MDS
Update | Pharmaceutical & Healthcare | 16/12/2011Sunesis’s lead product vosaroxin is to be included in a large investigator-sponsored trial (IST) that examines six different drug regimens in ac...
Sunesis Pharmaceuticals
Vosaroxin gets safety OK
Update | Pharmaceutical & Healthcare | 12/12/2011Sunesis’s development of vosaroxin has passed a small de-risking step, with the VALOR study’s independent Data and Safety Monitoring Board...
Sunesis Pharmaceuticals
R&D update, loan facility
Review | Pharmaceutical & Healthcare | 26/10/2011Sunesis’s principal investigators and collaborators provided a reassuring endorsement of the design and objectives of the VALOR study at the com...
Clavis Pharma
Morbid probabilities
QuickView | Pharmaceutical & Healthcare | 25/10/2011A trial to evaluate hENT1 levels in a sample of 500 pancreatic cancer patients has reported initial data showing around two thirds of patients have lo...
Sunesis Pharmaceuticals
Bravely taking on AML
Outlook | Pharmaceutical & Healthcare | 13/10/2011The investment case for Sunesis effectively rests entirely on the successful development and commercialisation of vosaroxin for acute myeloid leukaemi...
Clavis Pharma
Portfolio update
QuickView | Pharmaceutical & Healthcare | 06/05/2011The 5 May Q1 results focused on a new clinical candidate, CP-4200 for Mylodysplasia Syndrome (MDS), the precursor to Acute Myeloid Leukaemia (AML). Th...
Clavis Pharma
A hENT of success
QuickView | Pharmaceutical & Healthcare | 15/11/2010The 11 November Asian deal with Clovis (a well-funded US private pharma co) builds on the November 2009 Americas and EU deal. These now total $585m (w...
IS Pharma
Placing, dividends and Aloxi
Update | Pharmaceutical & Healthcare | 12/10/2010IS Pharma has placed 4.6m shares with Abingworth, a leading healthcare specialist fund, at a 9% premium – 77p to raise £3.55m. We expect IS Pharma ...
IS Pharma
High growth prospects
Outlook | Pharmaceutical & Healthcare | 01/07/2010Episil gives IS Pharma a further pan-European product alongside Variquel and Mysoline. The disposal of Volplex for £1.4m traded a low-growth, mature ...
IS Pharma
Focusing on higher growth
Update | Pharmaceutical & Healthcare | 04/05/2010Following the trading statement, we have re-evaluated IS Pharma in light of the new high-growth specialist products. Episil now gives a further pan-Eu...
IS Pharma
Episil for oral pain relief
Update | Pharmaceutical & Healthcare | 05/03/2010IS Pharma purchased the rights to sell Episil, an oral spray that creates a protective CrystalFilm over damaged mouth surfaces (oral mucositis). This ...
IS Pharma
2010 investment payback
Review | Pharmaceutical & Healthcare | 18/01/2010Following its early approval, Variquel, used to treat oesophageal bleeding in liver patients, had its launch brought forward. This momentum should giv...
IS Pharma
Second year in profit
Update | Pharmaceutical & Healthcare | 04/06/2009IS Pharma has reported a net profit for the second consecutive year, on revenue growth of 73%, following the takeover and integration of SEP Internati...
IS Pharma
Mutual recognition cleared
Update | Pharmaceutical & Healthcare | 16/03/2009IS Pharma’s Haemopressin has cleared the EU’s mutual recognition procedure, meaning that it is on track to be launched in an additional 14 E...
IS Pharma
Profitable first half
Update | Pharmaceutical & Healthcare | 05/11/2008IS Pharma’s first-half results confirm that the company is on track for its second profitable year, and the second half should see several new p...
IS Pharma
Ikaria deal triggers payment
Update | Pharmaceutical & Healthcare | 05/09/2008IS Pharma is to receive a $1.25m (c £640k) payment in FY09, triggered by a sub-licensing deal for Haemopressin/Lucassin (terlipressin). This deal...
IS Pharma
Profitable speciality pharma
Outlook | Pharmaceutical & Healthcare | 10/06/2008IS Pharma has reported maiden full-year net profits on the back of organic growth boosted by the acquisition of Acorus Therapeutics a year ago. The cu...
IS Pharma
Speciality focus expands
Outlook | Pharmaceutical & Healthcare | 31/03/2008Maelor has reached the next stage in its evolution as a speciality pharma company, last week announcing the £14m acquisition of Speciality Europe...
